Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BHP Billiton Limited (BHP) vs Cytokinetics Inc (CYTK) Price & Performance

BHP Billiton LimitedTrade
Cytokinetics IncTrade

Price performance (Past 24H)

Key statistics

BHP Billiton Limited vs Cytokinetics Inc — how do they compare? BHP Billiton Limited trades at $90.44 (market cap $227.94B), while Cytokinetics Inc trades at $76.66 (market cap $10.78B). The key difference: BHP Billiton Limited is far larger — about 21.1× Cytokinetics Inc's market cap, and BHP Billiton Limited pays a 2.94% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.

BHPCYTK
Market Cap
$227.94B$10.78B
Sector
Basic MaterialsTechnology
52-Week High
$93.15$87.26
52-Week Low
$52.14$34.31
Enterprise Value
$242.14B$10.88B
Dividend Yield
2.94%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BHP Billiton Limited

BHP trades at $90.41, up 2.86% today, with a bullish technical signal from moving averages and strong support at $88-89. The company maintains solid profitability with 18.97% net income margin and 20.13% ROE, though recent earnings showed a Q4 2025 miss. Current labor strikes at Port Hedland operations pose near-term operational risks while copper production declines in Chile.

BHP presents a mixed outlook with strong fundamentals offset by operational challenges. The stock's valuation appears reasonable with P/E of 22.46 and EV/EBITDA of 8.24, but analyst consensus leans cautious with 64.5% hold ratings. Key opportunities include AI-driven copper demand growth, while risks center on labor disputes and production volatility.

Cytokinetics Inc

Cytokinetics (CYTK) trades at $76.76, down 5.67% today, with a bearish technical signal and negative profitability metrics. Recent Q2 2026 earnings beat EPS estimates but missed on revenue, while the company's drug Myqorzo shows strong commercial uptake and regulatory approvals in the UK. Cash flow remains negative from operations, offset by financing activities.

The outlook is mixed: strong analyst buy ratings (97%) and a $111.14 price target suggest upside, but high cash burn, competitive pressures, and lack of profitability pose significant risks. Investment appeal hinges on successful drug commercialization and path to profitability.

Returns comparison

Trailing returns across standard periods

About BHP Billiton Limited

BHP Group Limited operates as a mining company. The Company engages in the exploration, development, production, and processing of iron ore, metallurgical coal, and copper. BHP Group serves customers worldwide.

Read more on BHP

About Cytokinetics Inc

Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.

Read more on CYTK